Press Releases



    • AUG 25 2015

    Enrollment Begins In Expansion Phase of ONC201 Clinical Trial

    Hummelstown, PA (August 25, 2015) –– Oncoceutics, Inc. announced that the first patients have been enrolled in the expansion phase of the first-in-man clinical trial with ONC201 at the Rutgers Cancer Institute of New Jersey (CINJ). Previously, Oncoceutics reported the completion of the dose escalation portion of the trial entitled “Oral ONC201 in Treating Patients

    • AUG 11 2015

    Analog of ONC201 Selected as Clinical Development Candidate

    Hummelstown, PA (August 11, 2015) – Oncoceutics, Inc. announced the selection of ONC212 to be the first development candidate from its portfolio of analogs derived from its lead compound ONC201. The decision to advance this analog follows the recent completion of a Phase I dose escalation study of ONC201 in patients with various treatment-refractory solid tumors

    • JUL 13 2015

    Fox Chase Cancer Center to Conduct ONC201 Dose Intensification Trial

    HUMMELSTOWN, PA (July 13, 2015) – Oncoceutics and Fox Chase Cancer Center have announced an agreement to conduct clinical testing with ONC201, a novel first-in-class small molecule compound being developed by the company. The study led by Dr. Anthony Olszanski, director of the Phase I Experimental Therapeutics Program at Fox Chase Cancer Center, will systematically

    • JUL 09 2015

    Oncoceutics Announces Completion of ONC201 First-in-Man Study

    Hummelstown, PA (July 9, 2015) – Oncoceutics, Inc. announced that enrollment has been completed in the first-in-man phase I dose escalation study of its lead compound, ONC201. The trial, identified as NCT02250781 on www.clinicaltrials.gov and entitled “Oral ONC201 in Treating Patients With Advanced Solid Tumors,” was carried out at Rutgers Cancer Institute of New Jersey